KR20120083359A - ＥｐＣＡＭｘＣＤ３ 이중특이성 항체를 투여하기 위한 투약 용법 - Google Patents

ＥｐＣＡＭｘＣＤ３ 이중특이성 항체를 투여하기 위한 투약 용법 Download PDF

Info

Publication number
KR20120083359A
KR20120083359A KR1020127007677A KR20127007677A KR20120083359A KR 20120083359 A KR20120083359 A KR 20120083359A KR 1020127007677 A KR1020127007677 A KR 1020127007677A KR 20127007677 A KR20127007677 A KR 20127007677A KR 20120083359 A KR20120083359 A KR 20120083359A
Authority
KR
South Korea
Prior art keywords
bispecific antibody
dose
epcamxcd3 bispecific
period
epcamxcd3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020127007677A
Other languages
English (en)
Korean (ko)
Inventor
저할드 주그메이어
피터 쿠퍼
도미니크 뤼팅거
사비네 카우비즈취
Original Assignee
마이크로메트 에이지
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 마이크로메트 에이지 filed Critical 마이크로메트 에이지
Publication of KR20120083359A publication Critical patent/KR20120083359A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020127007677A 2009-09-18 2010-09-20 ＥｐＣＡＭｘＣＤ３ 이중특이성 항체를 투여하기 위한 투약 용법 Withdrawn KR20120083359A (ko)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US24365109P 2009-09-18 2009-09-18
EP09170715 2009-09-18
US61/243,651 2009-09-18
EP09170715.8 2009-09-18
US34414710P 2010-06-01 2010-06-01
EP10164596 2010-06-01
EP10164596.8 2010-06-01
US61/344,147 2010-06-01

Publications (1)

Publication Number Publication Date
KR20120083359A true KR20120083359A (ko) 2012-07-25

Family

ID=43127167

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127007677A Withdrawn KR20120083359A (ko) 2009-09-18 2010-09-20 ＥｐＣＡＭｘＣＤ３ 이중특이성 항체를 투여하기 위한 투약 용법

Country Status (15)

Country Link
US (1) US20120244161A1 (cg-RX-API-DMAC10.html)
EP (1) EP2477653A1 (cg-RX-API-DMAC10.html)
JP (1) JP2013505223A (cg-RX-API-DMAC10.html)
KR (1) KR20120083359A (cg-RX-API-DMAC10.html)
CN (1) CN102711825A (cg-RX-API-DMAC10.html)
AU (1) AU2010297258A1 (cg-RX-API-DMAC10.html)
BR (1) BR112012008345A2 (cg-RX-API-DMAC10.html)
CA (1) CA2774732A1 (cg-RX-API-DMAC10.html)
IL (1) IL218637A0 (cg-RX-API-DMAC10.html)
IN (1) IN2012DN03172A (cg-RX-API-DMAC10.html)
MX (1) MX2012003175A (cg-RX-API-DMAC10.html)
NZ (1) NZ598601A (cg-RX-API-DMAC10.html)
RU (1) RU2012115480A (cg-RX-API-DMAC10.html)
SG (2) SG10201405434VA (cg-RX-API-DMAC10.html)
WO (1) WO2011033105A1 (cg-RX-API-DMAC10.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6400470B2 (ja) * 2011-05-16 2018-10-03 ジェネロン（シャンハイ）コーポレイション リミテッド 多重特異性Ｆａｂ融合タンパク質および使用法
AR089114A1 (es) 2011-12-09 2014-07-30 Amgen Res Munich Gmbh PREVENCION DE LOS EFECTOS ADVERSOS CAUSADOS POR LOS ANTICUERPOS BIESPECIFICOS EpCAMxCD3
GB201302447D0 (en) 2013-02-12 2013-03-27 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
RS61387B2 (sr) 2013-02-15 2024-06-28 Bioverativ Therapeutics Inc Gen optimizovanog faktora viii
WO2014131694A1 (en) * 2013-02-26 2014-09-04 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
US11046763B2 (en) * 2014-01-08 2021-06-29 The Board Of Trustees Of The Leland Stanford Junior University Targeted therapy for small cell lung cancer
US11008561B2 (en) 2014-06-30 2021-05-18 Bioverativ Therapeutics Inc. Optimized factor IX gene
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
HUE054131T2 (hu) 2015-11-19 2021-08-30 Revitope Ltd Funkcionális ellenanyag-fragmens-komplementáció nemkívánatos sejtek elpusztítására szolgáló kétkomponensû rendszerben
KR20180118659A (ko) 2016-02-01 2018-10-31 바이오버라티브 테라퓨틱스 인크. 최적화된 viii 인자 유전자
US12128102B2 (en) 2016-03-08 2024-10-29 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins
WO2017157305A1 (en) 2016-03-15 2017-09-21 Generon (Shanghai) Corporation Ltd. Multispecific fab fusion proteins and use thereof
WO2017167350A1 (en) * 2016-03-30 2017-10-05 Horst Lindhofer Multispecific antibodies for use in the treatment of a neoplasm of the urinary tract
EP3409322A1 (en) * 2017-06-01 2018-12-05 F. Hoffmann-La Roche AG Treatment method
CN111356700A (zh) 2017-09-08 2020-06-30 马弗里克治疗公司 受约束的条件性活化的结合蛋白
EP3847196A4 (en) 2018-09-07 2023-01-04 ITabMed (HK) Limited BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
WO2020132810A1 (en) 2018-12-24 2020-07-02 Generon (Shanghai) Corporation Ltd. Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof
EP4592313A3 (en) 2019-03-05 2025-11-19 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins
JP7803014B2 (ja) 2019-09-30 2026-01-21 バイオベラティブ セラピューティクス インコーポレイテッド レンチウイルスベクター製剤
JP2023537565A (ja) 2020-06-24 2023-09-04 バイオベラティブ セラピューティクス インコーポレイテッド タンパク質を発現するように改変されたレンチウイルスベクターの調製物から遊離第ｖｉｉｉ因子を除去する方法
CA3238406A1 (en) * 2021-11-19 2023-05-25 Wuhan Yzy Biopharma Co., Ltd. Bispecific antibody and use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02500329A (ja) 1987-05-21 1990-02-08 クリエイテイブ・バイオマリキユールズ・インコーポレーテツド ターゲット化多機能蛋白質
US8076459B2 (en) 2003-10-16 2011-12-13 Micromet Ag Multispecfic deimmunized CD3-binders
CA2606081C (en) * 2005-04-26 2013-09-17 Markus M. Heiss Combination of the application of antibodies for immunostimulation together with glucocorticoids

Also Published As

Publication number Publication date
IL218637A0 (en) 2012-05-31
JP2013505223A (ja) 2013-02-14
SG179027A1 (en) 2012-04-27
CA2774732A1 (en) 2011-03-24
AU2010297258A1 (en) 2012-03-29
SG10201405434VA (en) 2014-10-30
US20120244161A1 (en) 2012-09-27
NZ598601A (en) 2014-05-30
MX2012003175A (es) 2012-04-11
CN102711825A (zh) 2012-10-03
EP2477653A1 (en) 2012-07-25
WO2011033105A1 (en) 2011-03-24
IN2012DN03172A (cg-RX-API-DMAC10.html) 2015-09-25
BR112012008345A2 (pt) 2016-08-09
RU2012115480A (ru) 2013-10-27

Similar Documents

Publication Publication Date Title
US20120244161A1 (en) DOSAGE REGIMEN FOR ADMINISTERING AN EpCAMxCD3 BISPECIFIC ANTIBODY
JP2016534090A (ja) Ｃｄ３８アゴニストの医学的使用
KR20170007750A (ko) Ｈｐｖ-음성 암의 치료를 위한 ｐｄｌ-1의 길항제 및 ｐｄ-1의 길항제
CN114026126A (zh) 抗半乳糖凝集素-9抗体及其用途
CN112004828B (zh) 头颈癌的治疗
CN109793892B (zh) 一种抗pd-1抗体在制备治疗食管癌的药物中的用途
KR102947706B1 (ko) 암 치료를 위한 제약 조합물
AU2018353432A1 (en) Combination product for the treatment of cancer
WO2022232641A1 (en) Anti-galectin-9 antibodies and therapeutic uses thereof
TW202120550A (zh) 雙特異性蛋白質
KR20250116794A (ko) 항-ctla4 항체를 펨브롤리주맙과 조합하여 사용하여 암을 치료하는 방법
US20260085119A1 (en) Methods for treating cancer using anti-ctla4 antibodies
RU2833461C1 (ru) Способы лечения рака шейки матки путем введения инибитора pd-1
KR20260011225A (ko) 활성화 가능한 항-ctla4 항체를 펨브롤리주맙과 조합하여 사용하여 암을 치료하는 방법
KR20240082393A (ko) 항-갈렉틴-9 항체 및 이의 치료적 용도
HK40128545A (en) Use of anti-pd-1 antibodies in combination with chemotherapeutic agents for treating tumors
WO2025140324A1 (zh) 抗pd-1抗体联合化疗剂在治疗肿瘤中的用途
WO2025021073A1 (zh) 抗Nectin4抗体药物偶联物和抗PD-1抗体的药物组合以及其用途
CN115607663A (zh) 抗pd-1抗体在治疗原发纵隔大b细胞淋巴瘤中的应用
HK40069657A (en) Anti-galectin-9 antibodies and uses thereof
NZ729207A (en) Neutralization of inhibitory pathways in lymphocytes
NZ729207B2 (en) Neutralization of inhibitory pathways in lymphocytes

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20120323

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid